June 6, 2017
ORCA Therapeutics is attending the ASCO conference (June 2-6) in Chicago. Get in touch and come see us!

February 13, 2017
ORCA Therapeutics successfully completes preclinical studies on lead cancer drug candidate ORCA-010
READ MORE

September 25, 2016
VIRION Consortium first annual meeting held in Amsterdam
READ MORE

September 2016
Interview with ORCA’s CSO Victor van Beusechem in LabVision (Dutch)
READ MORE

May 25, 2016
On May 27th ORCA’s CSO Victor van Beusechem will give his inaugural lecture entitled: “El Dorado beyond the horizon”
READ MORE

May 4, 2016
ORCA Therapeutics receives Horizon 2020 grant for developing innovative virotherapy for treatment of melanoma
READ MORE

April 1, 2016
ORCA Therapeutics raises €1.5 million for funding nonclinical evaluation and GMP production of their lead product ORCA-010
READ MORE

Follow ORCA Therapeutics

Archive

Issuance of a new U.S. patent covering ORCA’s T1 oncolytic adenovirus technology

READ MORE

Publication Demonstrates Strong Preclinical Efficacy of ORCA’s lead Compound ORCA-010 in Different Tumor Models

READ MORE

ORCA Therapeutics strengthens Scientific Advisory Board

READ MORE

ORCA Therapeutics granted Chinese Patent covering its T1 oncolytic adenovirus technology

READ MORE

ORCA Therapeutics strengthens its Patent Portfolio

READ MORE

ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government

READ MORE

ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology

READ MORE

ORCA Therapeutics receives VCN License

READ MORE

ORCA Therapeutics B.V. receives grant from SenterNovem

READ MORE